

Australian Dementia Network (ADNeT) Registry 2020-2023 Status Report

A national clinical quality registry to drive continuous improvement in quality of care and patient outcomes from the time of diagnosis with dementia or mild cognitive impairment (MCI)

Contributing Sites



 **64**
Total sites

 **27%**
Regional sites

 **44%**
Private sites

Key Clinical Quality Indicators

60% First appointment within 90 days of referral


96% Core blood tests undertaken

99% Cognitive assessments completed

92% Structural neuroimaging completed

98% Ability to perform activities of daily living assessed

Cumulative Participant Recruitment



Impact

We have found the ADNeT Registry benchmarked data extremely useful in understanding our client profile and performance, as well as for the evaluation and future planning of our clinic.

**Associate Professor Jane Alty,
The ISLAND Clinic, Tasmania**

Median Diagnostic Wait Times



This infographic pertains to data submitted to the ADNeT Registry from commencement of data collection in March 2020 to December 2023 (n = 4280) unless indicated otherwise.

Australian Dementia Network (ADNeT) Registry 2020-2023 Status Report

✉ adnet.registry@monash.edu

☎ 1800 314 421

🌐 www.australiandementianetwork.org.au

Demographics

Median age (years) 78 years

Female 53%

First Nations people 1%

Born overseas 36%

Primary or lower education 10%

Living alone 26%

Diagnosis



34%
MCI



66%
Dementia

Dementia subtypes



53%
Alzheimer's
disease
only



23%
Mixed
Alzheimer's
& Vascular
dementia



13%
Others



11%
Vascular
dementia
only

Impact

The ADNeT Registry has provided important feedback on patient and family experience of our service, which we have shared with our executive to support growth in the Cognitive Dementia and Memory Service (CDAMS) service.

Associate Professor Mark Yates,
Grampians CDAMS, Grampians Health



Clinical Details

MCI		Dementia
40%	Neuropsychiatric symptoms ¹	52%
27%	Falls in past 12 months	34%
8%	Delirium history ¹	13%
56%	Polypharmacy ²	54%



Management Considerations

MCI		Dementia
Not collected	Referred to post-diagnostic program ¹	56%
6% ¹	Acetylcholinesterase Inhibitors	54%
50%	Future decision-maker appointed ¹	54%
66%	Driving	32%

This infographic pertains to data submitted to the ADNeT Registry from commencement of data collection in March 2020 to December 2023 (n = 4280) unless indicated otherwise.

¹ Data were collected from April 2023 (n = 1446, including 542 participants with MCI and 904 with dementia).

² Defined as having five or more regularly prescribed medications.



Australian
Dementia Network
REGISTRY. CLINICS. TRIALS.



MONASH
University